Down 28% from Oct 29 to Nov 10.
“Natera (NASDAQ:NTRA) delivers impressive Q3 2026 but stock drops 19.7%.”
Up 606% over the three years to Nov 9 while the S&P 500 rose 80%; down 28% since Oct 29.
8 reasons, from its filings, with the timeline, for Pro members.
NTRA's Quality Score fell 1 point on Tue, Nov 10, to 13. It closed away from its high of the day.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 37% on the year |
| Its score | Up:Above Average or better for 74 days in a row |
| Latest filing | 8-K, Nov 5 |
Natera appoints Solomon Moshkevich as new CEO
A results day: the move is left out.
After its last 4 reports it closed -2.1% on average, higher 1 of 4 times.
Above Averagefor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
NTRA is #5 of 18 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 5 |
Share count against a year before: NTRA +5%, GH +7.7%.
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $794.0M, 34% more than a year ago; a loss of $0.42 a share, from $0.64.
“The increase in revenues was driven by an increase in volume and average selling price improvements.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $790M | $748M | $590M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Revenue | $3.005B to $3.035B |
“This was primarily as a result of higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates.”
From its results filing (SEC filing · Nov 5)
Sales grew 43% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 11% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -12.0% | -14.6% | not yet |
| Aug 6, 2026 | +20.9% | +21.4% | +17.1% |
| May 7, 2026 | -4.5% | -11.6% | -10.4% |
Sales grew every year from 2018 to 2025, to $2.3B. It lost money in each of the eight years.
RSI 30.7, MACD below signal, below its 50-day, above its 200-day. Not scored.
2 insiders sold $19.6M across 10 filings in the last 6 months. No open-market buys on record. The newest:
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NTRA is 0.2% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
“The markets in which we operate are characterized by innovation and rapid change, and we primarily face competition from various companies that develop and commercialize molecular diagnostic tests in women’s health, oncology, and organ transplant rejection.”
NTRA scores 13 today, which Breakaway calls Above Average. It is #5 of 18 in Services-Medical Laboratories by Quality Score, with 1 of 14 chart checks firing. Down 28% from Oct 29 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NTRA scores 13 today, which Breakaway calls Above Average (11 to 14). That is #5 of 18 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NTRA's 13.
2 insiders sold $19.6M across 10 filings in the last 6 months. No open-market buys on record. The newest is Gail Boxer Marcus, Director, who sold $1M on Jun 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.